Lung cancer pill drastically cuts risk of death after surgery - Video
|
Overview
A once-daily pill halved people’s risk of dying from a common lung cancer when they took the drug after tumour-removal surgery, trial results from a global study show.
The research, published recently in The New England Journal of Medicine, found that taking the drug osimertinib after surgery dramatically reduced the risk of patients dying by 51 per cent.
The resaerchers randomly assigned eligible patients in a 1:1 ratio to receive osimertinib (80 mg once daily) or placebo until disease recurrence was observed.
For more medical news, check out the Medical Dialogue official site:
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
